CHR-1103
Phase 1- Indications
- Multiple sclerosis
Company intelligence / Profile preview
Chromos Molecular Systems Inc.
North Vancouver, British Columbia, Canadachromos.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Chromos Molecular Systems developed artificial chromosome technology and acquired Targeted Molecules Corporation to expand into antibody therapeutics for multiple sclerosis and thrombosis. Most clinical programs were discontinued or suspended, with no recent clinical results reported.
- Therapeutic areas
- OncologyPulmonologyNeurologyCardiovascularNephrology
- Modalities
- Artificial chromosome expression systemsAntibody therapeuticsPlatelet aggregation inhibitorsGPCR modulatorsExosome-based therapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Chromos Molecular Systems Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chromos Molecular Systems Inc..